ObjectivesOvarian tumors are among the most prominent gynecological malignancies and have a poor prognosis. Immunotherapy has undergone incredible progress in the past two decades. Our study aimed to

NIAID Data Ecosystem40

Supplementary Table S15 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

卵巢癌免疫治疗

生物标志物研究

Supplementary Table S15. Clinical characteristics of patients with HGSC according to RB1 and BRCA status.

NIAID Data Ecosystem30

Additional file 7: of Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer

卵巢癌免疫治疗

差异基因表达分析

Table S1. Differentially Expressed Genes MIS416 Vaxâ+âMRB-OVA vs Untreated. (XLS 26 kb)

NIAID Data Ecosystem60

Neoadjuvant and adjuvant pembrolizumab for advanced high-grade serous carcinoma (NeoPembrOV): A randomized phase II GINECO clinical trial

卵巢癌免疫治疗

肿瘤微环境分析

PD-1/PD-L1 blockade did not show survival benefit in high grade ovarian carcinomas. By using paired samples from the NeoPembrOv randomized phase II trial and by combining RNA-seq and multiplexed immun

NIAID Data Ecosystem40

Resistance of primary ovarian cancer cells to oncolytic adenoviruses part1 of 2

资源简介：

相关数据集